| Methods |
3‐ to 4‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 100‐114 mm Hg; 4‐week double‐blind treatment |
| Participants |
Ramipril 10 mg: n=67(44 males,23 females); mean age=53.8(9.8) years; baseline supine SBP=152.7(11.4) mm Hg, DBP=102.9(3.0) mm Hg;
Placebo: n=33(23 males,10 females); mean age=52.3(11.7) years; baseline supine SBP=151.9(13.2) mm Hg, DBP=102.1(3.0) mm Hg |
| Interventions |
Ramipril 10 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough standing SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SE reported, calculated SD of change from N and SE of change; BP data from Table III, p. 740; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
